Galectin prepares for secondary offering

|About: Galectin Therapeutics,... (GALT)|By:, SA News Editor

Galectin Therapeutics (GALT) files an S-3 for a $100M secondary offering of common stock plus 500,000 shares of common registered for sale by Richard Uihlein.

The offering includes a sales agreement with MLV & Co. for up to $30M of potential time-to-time future sales.

This was corrected on 03/24/2014 at 02:42 PM. The original item listed a "target price" of $16.50, but the price used was only a recent closing price, in compliance with SEC regulations. There is no definitive agreement with MLV on the $30M in sales.